One case in point is the development from the BCR-ABL allosteric inhibitor GNF-2 that will defeat the effect of resistant mutations as well as reveals an increased potency when used together with common ATP-competitive inhibitorsAn essential acquiring of the scientific trials in MPNs was the invention that JAK inhibition can be a valuable strategy … Read More